Why We Pursue Partnerships

Johnston Erwin 234x293This article comes from Johnston Erwin, Vice President of Corporate Business Development at Lilly. We’re excited to meet with top innovators and thought leaders at gatherings such as the 2017 J.P. Morgan Healthcare Conference, January 9-13.

Imagine a place where over 3,000 of the top minds in health care – from pharma and biotech, to academia and government – gather to share innovative ways to help patients. That’s the J.P. Morgan (JPM) Healthcare Conference in a nutshell.

Events like these are crucial to our work as true collaborators in the field of scientific research. In a way, these interactive, knowledge-sharing events are like sprints. We race from session to session, where experts spend every moment speedily sharing their insights and learning from each other.

But the running doesn’t end there. After the conference, we all dash back to our organizations to jump back onto the track for the marathon work of drug development.

Historically, the JPM Healthcare Conference, in particular, has helped us build partnerships that led to the development of some incredible modern medicines. At a past conference, we connected with Hanmi Pharmaceuticals and worked together to develop a BTK inhibitor, a medicine that treats serious autoimmune diseases. We’re excited to pursue more true collaborations with industry leaders at this year’s conference. The 2017 JPM Healthcare conference presents another exciting opportunity to make patients’ lives better. Through partnerships and collaboration, conferences like this one move us forward in our marathon work of drug discovery.

Learn more about collaborating with us here. You can follow our #JPM17 coverage on Twitter at @LillyPad.